Humana (NYSE:HUM) Stock Price Expected to Rise, Truist Financial Analyst Says

Humana (NYSE:HUMFree Report) had its target price increased by Truist Financial from $290.00 to $325.00 in a research report sent to investors on Friday,Benzinga reports. They currently have a hold rating on the insurance provider’s stock.

Several other brokerages have also recently commented on HUM. Mizuho boosted their target price on Humana from $305.00 to $316.00 and gave the stock an “outperform” rating in a report on Wednesday, April 9th. Cantor Fitzgerald reiterated a “neutral” rating and set a $290.00 price target on shares of Humana in a research report on Wednesday, February 12th. Guggenheim began coverage on Humana in a report on Wednesday, April 9th. They issued a “buy” rating and a $326.00 price objective for the company. JPMorgan Chase & Co. decreased their target price on Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research note on Tuesday, February 18th. Finally, Morgan Stanley dropped their price target on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 12th. Seventeen research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $288.60.

Check Out Our Latest Research Report on Humana

Humana Trading Up 1.6 %

NYSE:HUM opened at $294.97 on Friday. The stock has a market cap of $35.60 billion, a price-to-earnings ratio of 29.65, a PEG ratio of 2.05 and a beta of 0.62. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. Humana has a 1 year low of $213.31 and a 1 year high of $406.46. The business has a fifty day moving average of $265.55 and a 200-day moving average of $270.35.

Humana (NYSE:HUMGet Free Report) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Equities analysts predict that Humana will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.20%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s dividend payout ratio (DPR) is currently 35.58%.

Institutional Trading of Humana

Several hedge funds and other institutional investors have recently modified their holdings of HUM. FPC Investment Advisory Inc. acquired a new position in Humana during the fourth quarter valued at $27,000. Centricity Wealth Management LLC purchased a new position in Humana during the 4th quarter valued at about $30,000. LFA Lugano Financial Advisors SA increased its holdings in shares of Humana by 56.3% in the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares during the period. OFI Invest Asset Management acquired a new stake in shares of Humana during the fourth quarter worth approximately $33,000. Finally, Riverview Trust Co acquired a new stake in shares of Humana during the first quarter worth approximately $34,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Company Profile

(Get Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Further Reading

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.